Effect of Ginkgolide in Ischemic Stroke patients with large Artery Atherosclerosis : Results from a randomized trial
© 2021 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd..
BACKGROUND: Dual antiplatelet therapy is considered beneficial in acute ischemic stroke (AIS) patients with intracranial artery stenosis (ICAS), with more bleeding events. Ginkgolide is shown to reduce platelet activation after infarction, which might be of benefit in AIS. We aimed to explore the effect of Ginkgolide in AIS patients with ICAS.
METHODS: This was a randomized, double-blinded, placebo-controlled trial conducted at 61 centers in China. Within 72 h after onset, consecutive patients diagnosed as AIS with ICAS were randomized to either Ginkgolide or placebo treatment. The primary outcome was the composite of mortality and recurrent stroke (ischemic or hemorrhagic) during first 4 weeks in an intention-to-treat analysis. Secondary functional outcome was assessed by modified Rankin Scale and improvement of stroke severity was assessed by National Institution of Health Stroke Scale at day 28. Safety outcome was measured by the rate of severe adverse event (SAE).
RESULTS: There were 936 patients randomized to either Ginkgolide or placebo treatment. Their average age was 64.2 ± 10.4 years old and 36.0% of the patients were female. The composite index event occurred in six patients in placebo group, and none occurred in Ginkgolide group (risk ratio 1.01; 95% CI 1.00-1.02). There were more patients who achieved favorable outcome in Ginkgolide group, compared with that of the placebo group (OR 2.16, 95%CI 1.37-3.41). SAE occurred in five (1.1%) patients in the Ginkgolide group and three (0.6%) in the placebo group (OR0.60, 95CI% 0.14-2.53). Intracranial hemorrhage occurred in 1/473 (0.2%) in the placebo group.
CONCLUSIONS: Ginkgolide, working as PAF antagonist, may reduce recurrent stroke in AIS with ICAS patients within 72 hours after onset. It might be an optional treatment in moderate-to-severe AIS patients with ICAS. (http://www.chictr.org.cn Number as ChiCTR-IPR-17012310).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
CNS neuroscience & therapeutics - 27(2021), 12 vom: 01. Dez., Seite 1561-1569 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dong, Yi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute ischemic stroke |
|---|
| Anmerkungen: |
Date Completed 25.03.2022 Date Revised 04.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cns.13742 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332171388 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332171388 | ||
| 003 | DE-627 | ||
| 005 | 20240404232652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cns.13742 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM332171388 | ||
| 035 | |a (NLM)34676982 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dong, Yi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of Ginkgolide in Ischemic Stroke patients with large Artery Atherosclerosis |b Results from a randomized trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2022 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Dual antiplatelet therapy is considered beneficial in acute ischemic stroke (AIS) patients with intracranial artery stenosis (ICAS), with more bleeding events. Ginkgolide is shown to reduce platelet activation after infarction, which might be of benefit in AIS. We aimed to explore the effect of Ginkgolide in AIS patients with ICAS | ||
| 520 | |a METHODS: This was a randomized, double-blinded, placebo-controlled trial conducted at 61 centers in China. Within 72 h after onset, consecutive patients diagnosed as AIS with ICAS were randomized to either Ginkgolide or placebo treatment. The primary outcome was the composite of mortality and recurrent stroke (ischemic or hemorrhagic) during first 4 weeks in an intention-to-treat analysis. Secondary functional outcome was assessed by modified Rankin Scale and improvement of stroke severity was assessed by National Institution of Health Stroke Scale at day 28. Safety outcome was measured by the rate of severe adverse event (SAE) | ||
| 520 | |a RESULTS: There were 936 patients randomized to either Ginkgolide or placebo treatment. Their average age was 64.2 ± 10.4 years old and 36.0% of the patients were female. The composite index event occurred in six patients in placebo group, and none occurred in Ginkgolide group (risk ratio 1.01; 95% CI 1.00-1.02). There were more patients who achieved favorable outcome in Ginkgolide group, compared with that of the placebo group (OR 2.16, 95%CI 1.37-3.41). SAE occurred in five (1.1%) patients in the Ginkgolide group and three (0.6%) in the placebo group (OR0.60, 95CI% 0.14-2.53). Intracranial hemorrhage occurred in 1/473 (0.2%) in the placebo group | ||
| 520 | |a CONCLUSIONS: Ginkgolide, working as PAF antagonist, may reduce recurrent stroke in AIS with ICAS patients within 72 hours after onset. It might be an optional treatment in moderate-to-severe AIS patients with ICAS. (http://www.chictr.org.cn Number as ChiCTR-IPR-17012310) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a PAF | |
| 650 | 4 | |a acute ischemic stroke | |
| 650 | 4 | |a ginkgolide | |
| 650 | 4 | |a intracranial stenosis | |
| 650 | 7 | |a Ginkgolides |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 700 | 1 | |a Zhang, Jingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanxia |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Lihong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Runhui |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Chunhua |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Qingke |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Lishu |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Liping |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Shejun |e verfasserin |4 aut | |
| 700 | 1 | |a You, Mingyao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hongtian |e verfasserin |4 aut | |
| 700 | 1 | |a He, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Qiang |e verfasserin |4 aut | |
| 700 | 0 | |a GISAA committee |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Lei |e investigator |4 oth | |
| 700 | 1 | |a Cao, Wenjie |e investigator |4 oth | |
| 700 | 1 | |a Xu, Dongjuan |e investigator |4 oth | |
| 700 | 1 | |a Guo, Jianjun |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Jiadong |e investigator |4 oth | |
| 700 | 1 | |a Chen, Guofang |e investigator |4 oth | |
| 700 | 1 | |a Wei, Yan |e investigator |4 oth | |
| 700 | 1 | |a Hou, Shuangxing |e investigator |4 oth | |
| 700 | 1 | |a Mao, Xijing |e investigator |4 oth | |
| 700 | 1 | |a Ji, Rongxia |e investigator |4 oth | |
| 700 | 1 | |a Long, Jifa |e investigator |4 oth | |
| 700 | 1 | |a Chen, Caixiao |e investigator |4 oth | |
| 700 | 1 | |a Zhao, Yong |e investigator |4 oth | |
| 700 | 1 | |a Li, Guozhong |e investigator |4 oth | |
| 700 | 1 | |a Yu, Wenjun |e investigator |4 oth | |
| 700 | 1 | |a Xu, Jianhua |e investigator |4 oth | |
| 700 | 1 | |a Pu, Xiangyu |e investigator |4 oth | |
| 700 | 1 | |a Li, Xiaohong |e investigator |4 oth | |
| 700 | 1 | |a Jiang, Zhilin |e investigator |4 oth | |
| 700 | 1 | |a Yang, Yi |e investigator |4 oth | |
| 700 | 1 | |a Li, Wei |e investigator |4 oth | |
| 700 | 1 | |a Zeng, Qingyou |e investigator |4 oth | |
| 700 | 1 | |a Sun, Tao |e investigator |4 oth | |
| 700 | 1 | |a Song, Yingmin |e investigator |4 oth | |
| 700 | 1 | |a Wang, Baoshen |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Guiru |e investigator |4 oth | |
| 700 | 1 | |a Chen, Huisheng |e investigator |4 oth | |
| 700 | 1 | |a Liu, Junyan |e investigator |4 oth | |
| 700 | 1 | |a Liu, Zhenguo |e investigator |4 oth | |
| 700 | 1 | |a Hou, Yongge |e investigator |4 oth | |
| 700 | 1 | |a Zong, Biyun |e investigator |4 oth | |
| 700 | 1 | |a Liu, Jun |e investigator |4 oth | |
| 700 | 1 | |a Wu, Bihua |e investigator |4 oth | |
| 700 | 1 | |a Wang, Xin |e investigator |4 oth | |
| 700 | 1 | |a Qin, Ding |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Ming |e investigator |4 oth | |
| 700 | 1 | |a Gu, Weizhong |e investigator |4 oth | |
| 700 | 1 | |a Chen, Houqin |e investigator |4 oth | |
| 700 | 1 | |a He, Qing |e investigator |4 oth | |
| 700 | 1 | |a Xu, Anding |e investigator |4 oth | |
| 700 | 1 | |a Xu, Yun |e investigator |4 oth | |
| 700 | 1 | |a Yan, Mingzong |e investigator |4 oth | |
| 700 | 1 | |a Feng, Xiaoya |e investigator |4 oth | |
| 700 | 1 | |a Tan, Jun |e investigator |4 oth | |
| 700 | 1 | |a Sun, Ping |e investigator |4 oth | |
| 700 | 1 | |a Lu, Zhengqi |e investigator |4 oth | |
| 700 | 1 | |a Bo, Xiao |e investigator |4 oth | |
| 700 | 1 | |a Jiao, Zhen |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t CNS neuroscience & therapeutics |d 2008 |g 27(2021), 12 vom: 01. Dez., Seite 1561-1569 |w (DE-627)NLM17958930X |x 1755-5949 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:12 |g day:01 |g month:12 |g pages:1561-1569 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cns.13742 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 12 |b 01 |c 12 |h 1561-1569 | ||